AbdullahKutlarMD

PubMed

• 640 citations
  Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment
  Martin H. Steinberg, Franca B. Barton, Oswaldo Castro, Charles H. Pegelow, Samir K. Ballas
  JAMA. 2003-04-02
• 66 citations
  Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
  Vivien A. Sheehan, Zhaoyu Luo, Jonathan M. Flanagan, Thad A. Howard, Bruce W. Thompson
  American Journal of Hematology. 2013-07-01
• 191 citations
  American Society of Hematology 2020 guidelines for sickle cell disease: Management of acute and chronic pain
  Amanda M. Brandow, C. Patrick Carroll, Susan E Creary, Ronisha Edwards-Elliott, Jeffrey Glassberg
  Blood Advances. 2020-06-23

Abstracts/Posters

• Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies
  Abdullah Kutlar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study
  Abdullah Kutlar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Downregulation of Cytoskeletal Protein Kazrin in Lung Endothelial Cells of Preclinical Sickle Cell Disease Mouse Model - Essential Role of Endothelial Barrier Function
  Abdullah Kutlar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• Established Prevention of Vaso-Occlusive Crises with Crizanlizumab Is Further Improved in Patients Who Follow the Standard Treatment Regimen: Post-Hoc Analysis of the ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Other

• Laboratory diagnosis of the hemoglobinopathies 
  Kutlar A, Kutlar F
  http://www.uptodate.com/contents/laboratory-diagnosis-of-the-hemoglobinopathies
  UpToDate, Wolters Kluwer Health - 2012-03-13